Clinical Trial Update: A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients. [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating 3 mg Efsubaglutide Alfa injected every two weeks in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Efsubaglutide Alfa Injection (Efsubaglutide Alfa)

Snippet

Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Conditions: Type2 Diabetes | Phase 2 | Status: COMPLETED